SGAM
Smith Group Asset Management Portfolio holdings
AUM
$1.53B
1-Year Return
38.67%
This Quarter Return
+31.89%
1 Year Return
+38.67%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.81B
AUM Growth
-$18.2M
(-0.99%)
Cap. Flow
-$453M
Cap. Flow
% of AUM
-24.96%
Top 10 Holdings %
Top 10 Hldgs %
40.04%
Holding
396
New
38
Increased
53
Reduced
183
Closed
98
Top Buys
| 1 |
Hologic
HOLX
|
$28M |
| 2 |
Parker-Hannifin
PH
|
$23.7M |
| 3 |
Ameriprise Financial
AMP
|
$18.5M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$12.9M |
| 5 |
Lowe's Companies
LOW
|
$12.9M |
Top Sells
| 1 |
Apple
AAPL
|
$57.1M |
| 2 |
Microsoft
MSFT
|
$51M |
| 3 |
Biogen
BIIB
|
$36M |
| 4 |
Amazon
AMZN
|
$33.9M |
| 5 |
Burlington
BURL
|
$25.3M |
Sector Composition
| 1 | Technology | 38.49% |
| 2 | Healthcare | 16.85% |
| 3 | Consumer Discretionary | 12.94% |
| 4 | Communication Services | 8.43% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Xencor
XNCR
$610M
| $57K | ﹤0.01% |
1,760
-4,405
| -71% | -$143K |
|
202
TotalEnergies
TTE
$133B
| $50K | ﹤0.01% |
1,306
+210
| +19% | +$8.04K |
|
203
Bank of America
BAC
$369B
| $49K | ﹤0.01% |
2,045
-805,793
| -100% | -$19.3M |
|
|
ICPT
204
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $49K | ﹤0.01% |
1,030
-20
| -2% | -$951 |
|
|
ALLK
205
DELISTED
Allakos
ALLK
| $47K | ﹤0.01% |
650
-10
| -2% | -$723 |
|
206
Citigroup
C
$176B
| $43K | ﹤0.01% |
840
+2
| +0.2% | +$102 |
|
207
Ironwood Pharmaceuticals
IRWD
$188M
| $43K | ﹤0.01% |
4,140
-30
| -0.7% | -$312 |
|
|
CEO
208
DELISTED
CNOOC Limited
CEO
| $43K | ﹤0.01% |
377
+60
| +19% | +$6.84K |
|
209
Regenxbio
RGNX
$490M
| $42K | ﹤0.01% |
1,140
-20
| -2% | -$737 |
|
210
DuPont de Nemours
DD
$32.6B
| $41K | ﹤0.01% |
771
+132
| +21% | +$7.02K |
|
211
Heron Therapeutics
HRTX
$201M
| $41K | ﹤0.01% |
2,810
-30
| -1% | -$438 |
|
212
Wells Fargo
WFC
$253B
| $40K | ﹤0.01% |
1,561
+300
| +24% | +$7.69K |
|
213
Blackrock
BLK
$170B
| $39K | ﹤0.01% |
71
+2
| +3% | +$1.1K |
|
214
Allstate
ALL
$53.1B
| $36K | ﹤0.01% |
367
-5
| -1% | -$490 |
|
215
Linde
LIN
$220B
| $36K | ﹤0.01% |
169
+110
| +186% | +$23.4K |
|
216
US Bancorp
USB
$75.9B
| $36K | ﹤0.01% |
987
-5
| -0.5% | -$182 |
|
217
Enanta Pharmaceuticals
ENTA
$189M
| $36K | ﹤0.01% |
720
-20
| -3% | -$1K |
|
218
ENI
E
$51.4B
| $35K | ﹤0.01% |
1,796
+300
| +20% | +$5.85K |
|
219
Enbridge
ENB
$105B
| $35K | ﹤0.01% |
1,143
+190
| +20% | +$5.82K |
|
|
PTLA
220
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $35K | ﹤0.01% |
1,970
-20
| -1% | -$355 |
|
221
Dow Inc
DOW
$17.4B
| $34K | ﹤0.01% |
830
+130
| +19% | +$5.33K |
|
222
PNC Financial Services
PNC
$80.5B
| $34K | ﹤0.01% |
322
-5
| -2% | -$528 |
|
223
LyondellBasell Industries
LYB
$17.7B
| $33K | ﹤0.01% |
507
+130
| +34% | +$8.46K |
|
224
Morgan Stanley
MS
$236B
| $31K | ﹤0.01% |
639
-20
| -3% | -$970 |
|
|
RDS.B
225
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $31K | ﹤0.01% |
1,002
+160
| +19% | +$4.95K |
|